Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Cryo-EM reveals the molecular basis of SARS-CoV-2 cross-neutralization by the monoclonal antibody 47D11.
Article activity feed
-
-
SciScore for 10.1101/2020.09.30.318261: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources Plates were washed three times and incubated with horseradish peroxidase (HRP)-conjugated goat anti-human secondary antibody (ITK Southern Biotech) diluted 1:2000 in blocking buffer for 1 hour at RT. anti-human secondary antibody (ITKsuggested: NoneExperimental Models: Cell Lines Sentences Resources HEK-293T cells were transfected with pCAGGS expression vectors encoding SARS2-S carrying a 18-a.a. cytoplasmic tail truncation, respectively. HEK-293Tsuggested: NoneSoftware and Algorithms Sentences Resources The half maximal inhibitory concentration (IC50) was determined using 4-parameter logistic regression … SciScore for 10.1101/2020.09.30.318261: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources Plates were washed three times and incubated with horseradish peroxidase (HRP)-conjugated goat anti-human secondary antibody (ITK Southern Biotech) diluted 1:2000 in blocking buffer for 1 hour at RT. anti-human secondary antibody (ITKsuggested: NoneExperimental Models: Cell Lines Sentences Resources HEK-293T cells were transfected with pCAGGS expression vectors encoding SARS2-S carrying a 18-a.a. cytoplasmic tail truncation, respectively. HEK-293Tsuggested: NoneSoftware and Algorithms Sentences Resources The half maximal inhibitory concentration (IC50) was determined using 4-parameter logistic regression (GraphPad Prism version 8). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Half-maximum effective concentration (EC50) binding values were calculated by non-linear regression analysis on the binding curves using GraphPad Prism (version 8). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Cryo-EM data processing: Single-particle analysis was performed in Relion version 3.1.(52). Relionsuggested: (RELION, RRID:SCR_016274)Drift and gain correction were performed with MotionCor2(53), CTF parameters were estimated using CTFFind4(54) and particles were picked using the Laplacian picker in Relion(52). MotionCor2suggested: (MotionCor2, RRID:SCR_016499)Model building and refinement: UCSF Chimera (version 1.12.0) and Coot (version, 1.0.) were used for model building and analysis(55, 56). Cootsuggested: (Coot, RRID:SCR_014222)Phenix sculptor was used to create an initial model for the Fab chains(60), removing the non-aligning regions (notably the CDRH3). Phenixsuggested: (Phenix, RRID:SCR_014224)Models were refined against the respective EM density maps using Phenix Real Space Refinement and Isolde(61)(62), and validated with MolProbity and Privateer (glycans)(63–65). MolProbitysuggested: (MolProbity, RRID:SCR_014226)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-